TSE:JWEL

Jamieson Wellness (JWEL.TO)

40.18
+3.79 (10.41%)
as of Jun 25, 2026, 8:00:00 pm Market Open.
152 watching
0
Investor Insights
star iconJun 25, 2026, 12:00 am

This summary was created by AI, based on 1 opinions in the last 12 months.

Jamieson Wellness, symbol JWEL-T, has established itself as a solid player in the Canadian wellness sector, particularly noted for its high-quality products and stable growth trajectory. Founded in Windsor, Ontario, the company has expanded its footprint by acquiring a California-based firm, effectively mitigating risks associated with tariffs. With a keen focus on the burgeoning Chinese market, Jamieson's commitment to quality distinguishes it from competitors. Over the past five years, the company has impressively increased its dividend payouts at an average rate of 14%, attracting attention from investors seeking dependable income streams. At a current yield of 2.55% and with analysts projecting a price target of $42.43, there seems to be strong potential for future appreciation, reinforcing its status as an appealing option for portfolio enhancement.

consensus icon
Consensus
Positive
valuation icon
Valuation
Fair Value
review icon
Similar
DS-CMM
TOP PICK
Recent price drop has presented good buying opportunity 25% share of the Canadian vitamin and supplement market. Growing international sales with the help of other companies such as Costco. Large acquisition announced last week will provide entry point into the US market. EPS significantly rising (20x ) at the moment.
BUY

Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. EPS at 34 cents that beat estimates by 2%. Sales of $112.3M were reported. Generally a good quarter. The focus on post covid health trends continue to be a tailwind. Attractive here. Unlock Premium - Try 5i Free

BUY ON WEAKNESS
Interesting, good company, profitable. A bit rich now. He was worried about private labels taking market share. Could buy it on the right dip. He's looking at it.
BUY

Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. Revenues beat street estimates by 4%. EBITDA was 2% better at $29M. It is trading at 26x earnings, which is reasonably considering the high growth expectations. There are competitors but they have strong market share. A higher risk buy for growth and some income. Unlock Premium - Try 5i Free

BUY
She does not follow that small a capitalization stock closely. They are a well positioned player in the space. Their growth opportunities look positive.
WATCH
A great company and it has profited from the pandemic. People are becoming more health conscious. It is well-positioned to take advantage of the trend. Earnings still have a ways to grow to make the multiples attractive. Trailing 12-month earnings are .64 cents, which makes it at 36x earnings. He would like to see it more around 25x earnings, around the mid-to-high 20s.
BUY ON WEAKNESS

Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. Business has reamiend good and earnings growth continues to be expected. They raised dividends in August with more room to grow. The $6 decline is probably over done. Unlock Premium - Try 5i Free

BUY

Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. Sales beat expectations by 6% and earnings also beat estimates by 2%. Guidance was raised, which is also positive. The pull back that brought it down 16% is more market related than to do with the stock itself. It is a good time to add to this position. Unlock Premium - Try 5i Free

BUY

Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research.  Covid has helped the company with consumers more aware of health. They beat sale estimates last quarter but missed on EPS. It’s trading within its expected growth rate. The health trend should be sustained even after covid. Unlock Premium - Try 5i Free

BUY ON WEAKNESS
Just looking at your local drug store, all the shelves have been stripped bare for their products. People are taking more supplements and he thinks that will continue. The stock is at 29 times PE, but technically it is bullish. He thinks analysts will continue to increase earnings outlooks to justify the costs.
BUY
A fine IPO performer; they did a good job to ensure that private equity fund involved got cleaned out, so that overhang didn't happen. They just put out a strong report with good international growth. This may be added to an index. Not a cheap stock, but they boast earnings growth and a strong brand. He owns a lot of this.
HOLD
They did a good job of getting the private equity guys out of it so there was lots for individual investors. They are gearing up for a better second half.
HOLD
Vitamins and health supplements, protein supplements. They missed on earnings. It is a great Canadian company. A pickup in the cold and flu season would benefit them. They are trying to penetrate the Chinese market. They Manufacture in Winsor and Scarborough.
WATCH
A stable, high-quality business. When it IPO'd, the market over-rewarded it, but the stock has since corrected to something attractive. The healthy trend works for them. he's studying it.
HOLD

He likes the trend towards health and wellness through supplements and protein shakes. The company has been given a license to sell their branded product in China. His fund will continue to hold this stock.

Showing 16 to 30 of 34 entries